Our study uncovered a new mechanism by which Dex exacerbates lung metastasis by breast cancer cells through PI3K-SGK1-CTGF signaling and raises concerns about the risk of Dex pre-treatment in breast cancer chemotherapy. Here, CCN2 is linked to breast carcinoma.